Andrew Beck, PathAI CEO and co-founder

Glax­o­SmithK­line keeps truck­ing along­side AI with new, mul­ti-year pathol­o­gy part­ner­ship with Boston out­fit

Big Phar­ma has been in hot pur­suit of the al­lure of AI in­te­gra­tion, with the al­leged po­ten­tial for rev­o­lu­tion­iz­ing drug R&D. The UK’s Glax­o­SmithK­line has been no ex­cep­tion, with its part­ner­ships in the past with King’s Col­lege for per­son­al­ized on­col­o­gy treat­ments and with Cere­bras for ac­cess to its su­perAI plat­form.

In­tro­duce Boston AI biotech PathAI. Af­ter al­ready align­ing arms with Bris­tol My­ers Squibb, the six-year-old start­up is link­ing up with GSK. It’s a big get for PathAI, which closed a Se­ries B in 2019, bag­ging $75 mil­lion in the process and, two years lat­er, $165 mil­lion in a Se­ries C.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.